Education
About Us
Working with TipRanks
Follow Us
Rxsight, Inc. (RXST)
:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.32 - $58.23
Previous CloseN/A
Volume110.15K
Average Volume (3M)1.70M
Market Cap
$310.87M
Enterprise Value$805.57M
Total Cash (Recent Filing)$229.34M
Total Debt (Recent Filing)$12.04M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 06, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding40,636,982
10 Day Avg. Volume941,958
30 Day Avg. Volume1,699,821
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.59
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit7.56
Enterprise Value/Ebitda-30.41
Forecast
1Y Price Target
$11.75Price Target Upside53.59% Upside
Rating ConsensusHold
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
International ExpansionOUS expansion offers sizeable future opportunity, with approvals in Korea and the EU, and expectations to enter more countries.
Market ValuationRXST's valuation appears very attractive, trading at a significant discount to its peers, with above-average growth, a strong moat, and high gross margins.
Bears Say
Market CompetitionIncreased competitive pressures from recent multifocal IOL launches are impacting RXST.
Revenue GuidanceRXST cut 2025 revenue guidance by 25% after cutting it 12% in Q1.
Revenue PerformanceRXST preannounced Q2 revenue of $33.6m, missing Street consensus by $6m or 16%.
RxSight News
RXST FAQ
What was Rxsight, Inc.’s price range in the past 12 months?
Rxsight, Inc. lowest stock price was $6.32 and its highest was $58.23 in the past 12 months.
What is Rxsight, Inc.’s market cap?
Rxsight, Inc.’s market cap is $310.87M.
When is Rxsight, Inc.’s upcoming earnings report date?
Rxsight, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Rxsight, Inc.’s earnings last quarter?
Rxsight, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.248 by -$0.042.
Is Rxsight, Inc. overvalued?
According to Wall Street analysts Rxsight, Inc.’s price is currently Undervalued.
Does Rxsight, Inc. pay dividends?
Rxsight, Inc. does not currently pay dividends.
What is Rxsight, Inc.’s EPS estimate?
Rxsight, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Rxsight, Inc. have?
Rxsight, Inc. has 40,636,982 shares outstanding.
What happened to Rxsight, Inc.’s price movement after its last earnings report?
Rxsight, Inc. reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.248. Following the earnings report the stock price went down -11.208%.
Which hedge fund is a major shareholder of Rxsight, Inc.?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.75 (53.59% Upside)
$11.75 (53.59% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 447.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.22%
12-Months-Change
Fundamentals
Return on Equity
-11.98%
Trailing 12-Months
Asset Growth
70.91%
Trailing 12-Months
Company Description
Rxsight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed strong revenue growth and customer satisfaction but was overshadowed by the revision of revenue guidance due to macroeconomic challenges and market competition. While European regulatory approval presents a long-term opportunity, short-term challenges persist, affecting performance and outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$11.75
▲(53.59% Upside)
Technical Analysis
Ownership Overview
5.52% Insiders
17.21% Mutual Funds
1.21% Other Institutional Investors
56.25% Public Companies and
Individual Investors